View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 5, 2011

Sanofi Signs Antibiotics Research Collaboration Deal

France-based pharmaceutical major Sanofi has signed a worldwide research collaboration with Rib-X Pharmaceuticals to develop novel antibiotics. The agreement also includes an option to licence the drugs resulting from Rib-X's RX-04 program, used to treat resistant Gram-positive and G

By cms admin

France-based pharmaceutical major Sanofi has signed a worldwide research collaboration with Rib-X Pharmaceuticals to develop novel antibiotics.

The agreement also includes an option to licence the drugs resulting from Rib-X’s RX-04 program, used to treat resistant Gram-positive and Gram-negative pathogens.

Under the terms of the agreement, Rib-X will receive an upfront payment of $10m and will be eligible to receive a further $9m relating to milestone payments relating to research, pre-clinical, regulatory and commercial milestones.

Sanofi will retain the right to develop multiple products under the agreement, whereas Rib-X will keep its rights to the discovery platform and future programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology